@article{94bc5bc392ba4e18a781b5a493c30666,
title = "The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs",
keywords = "Cholangiocarcinoma, biliary tract cancer, extrahepatic cholangiocarcinoma, fibroblast growth factor receptor, genetics, genomic profiling, intrahepatic cholangiocarcinoma, isocitrate dehydrogenase, targeted therapies",
author = "Sipra, \{Qurat Ul Ain Riaz\} and Rachna Shroff",
note = "Funding Information: R Shroff is an Advisory Board Member for Merck, Seattle Genetics, QED Therapeutics, DebiPharm, Agios, Clovis, Exelixis, and Incyte. She also receives research funding from Merck, Haloyzme, Pieris, Taiho, Rafael Pharmaceuticals, and Exelixis Pharmaceuticals. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. ",
year = "2021",
doi = "10.1080/13543784.2021.1849139",
language = "English (US)",
volume = "30",
pages = "281--284",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "4",
}